Amazon Web Services Extends Deal With Zoom

(RTTNews) – Amazon’s cloud platform Amazon Web Services or AWS announced an extension to its agreement with Zoom Video Communications, Inc. to be its preferred cloud provider.

The multi-year agreement is expected to enable Zoom to rise to the challenges brought by the COVID-19 pandemic.

Zoom will continue to leverage AWS’s global infrastructure and portfolio of services, including capabilities in compute, storage, content distribution, and security.

With AWS’s portfolio of services, Zoom could grow its core video meeting platform and innovate new customer experiences for its corporate and individual customers, Amazon said in a statement.

The companies are also collaborating to develop new solutions for Zoom’s enterprise users.

Zoom, which was in partnership with AWS since 2011, expanded its relationship earlier this year to keep up with surging demand amid the COVID-19 pandemic crisis. According to the company, hundreds of millions of new Zoom participants began to use the platform

Read More

Ufovax Extends Its Intellectual Property Portfolio to Include a Patent Covering the Design of an Optimized Antigen For COVID-19

Ufovax, LLC, (Ufovax), a vaccine biotechnology company based on the Single-component Self-Assembling protein NanoParticle (1c-SApNP) vaccine design and manufacturing platform invented by Associate Professor Jiang Zhu, PhD, of Scripps Research (La Jolla, CA), has extended its intellectual property portfolio to include an exclusive global license to a patent covering the design of an optimized antigen for SARS-CoV-2 (aka “COVID-19”). The patent, entitled Stabilized Coronavirus Spike (S) Protein Immunogens and Related Vaccines, was filed by Scripps Research on June 29th of this year and was allowed by the U.S. Patent & Trademark Office (USPTO) on Nov 24, 2020.

Described earlier this year in a submission available on the bioRxiv preprint server, a systematic study of five antigen designs was completed along with evaluation of vaccine response in mice. Using the popular S2P mutation of the Spike alone, the optimized spike antigen design (S2GΔHR2) alone and the

Read More

Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for …

CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease.

“We are very pleased with the progress to date in our ongoing strategic collaboration with Merck,” said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. “Extending the research term of our agreement based on promising preclinical data with a goal of identifying a clinical candidate underscores the significant potential of our therapeutic Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform and CUE-300 series in the treatment of debilitating

Read More

Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck

CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease.

“We are very pleased with the progress to date in our ongoing strategic collaboration with Merck,” said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. “Extending the research term of our agreement based on promising preclinical data with a goal of identifying a clinical candidate underscores the significant potential of our therapeutic Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform and CUE-300 series in the treatment of debilitating

Read More

Open Source Software Terrascan Extends Policy as Code Support to Helm, Kustomize

OPA-Based architecture eases governance across multiple cloud native technologies

From KubeCon + CloudNativeCon North America – Accurics, the cloud cyber resilience specialist, today announced that Terrascan, the open source static code analyzer that enables developers to build secure infrastructure as code (IaC), has been extended to support Helm and Kustomize, both projects from the Cloud Native Computing Foundation (CNCF) that have gained immense popularity. This enables organizations to ensure applications on Kubernetes clusters are secure and compliant before they are deployed.

“Given the increasing scale and velocity of cloud breaches, organizations need policy guardrails to ensure that cloud native infrastructure is securely defined and managed,” said Cesar Rodriguez, creator of Terrascan and head of Developer Advocacy at Accurics. “Now, with the additional support for Helm and Kustomize, teams using Terrascan to programmatically establish Policy as Code guardrails in their high-velocity, component-based Kubernetes projects have a way to reduce security

Read More

Facebook extends political ad ban another month as Trump refuses to concede

Facebook on Wednesday announced an extension on its political advertising ban for at least another month, citing delays in election results due to COVID-19 and unprecedented rates of mail-in and absentee voting. The extension was announced in an update posted to its original blog post on the topic.

“The temporary pause for ads about politics and social issues in the US continues to be in place as part of our ongoing efforts to protect the election. Advertisers can expect this to last another month, though there may be an opportunity to resume these ads sooner,” the update reads. “Getting the US election results this year may take longer than in previous elections due to the coronavirus (COVID-19) pandemic and more people voting by mail. We’ve introduced a range of policies and products to help protect the integrity of the election and reduce opportunities for confusion or abuse.”

What Facebook does

Read More